Clinical Trials Logo

Clinical Trial Summary

Safety and immunogenicity of the investigational V184 chikungunya vaccine will be tested in participants with history of chikungunya infection. Initially 21 to 50 year old participants will be enrolled; after favorable review of safety data, participants aged 51 to 65 will be enrolled.


Clinical Trial Description

This will be a randomized double-blind interventional clinical study. This study proposes to evaluate the safety and immunogenicity of the investigational V184 live recombinant measles-vectored chikungunya vaccine delivered in 2 vaccinations, 28 days apart compared with saline placebo. After providing informed consent, individuals will be screened for eligibility including verification of previous exposure to chikungunya virus. They will then be randomized in a double-blind fashion to receive either V184 or saline placebo in a 1:1 ratio. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03807843
Study type Interventional
Source Themis Bioscience GmbH
Contact
Status Completed
Phase Phase 2
Start date July 16, 2019
Completion date May 13, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT02230163 - Clinical Evaluation of Anti-CHIKV Hyperimmune Intravenous Immunoglobulins Phase 1/Phase 2
Completed NCT04546724 - Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults Phase 3
Terminated NCT04455919 - Yoga for Chronic Chikungunya N/A
Completed NCT03631719 - Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia
Active, not recruiting NCT04441905 - Phase 1 Study of SAR440894 vs Placebo Phase 1
Completed NCT02562482 - Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults Phase 2
Completed NCT03028441 - Phase I Trial of Measles Vectored Chikungungya Vaccine Phase 1
Completed NCT04909411 - Consequences of a Maternal-fetal Chikungunya Virus Infection N/A
Completed NCT04786444 - Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults Phase 3
Completed NCT02553369 - Seroprevalence of Chikungunya at the End of the First Chikungunya Outbreak in the French Antilles Within a Sample of Patients Treated for a HIV Infection N/A
Recruiting NCT06106581 - A Phase 2 Clinical Study of VLA1553 in Healthy Children Aged 1 to 11 Years Phase 2
Recruiting NCT06007183 - Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination Phase 3
Completed NCT03635086 - Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005) Phase 2
Completed NCT02861586 - Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine Phase 2
Active, not recruiting NCT04838444 - Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine Candidate (VLA1553) Phase 3
Completed NCT03483961 - Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults Phase 2
Recruiting NCT06028841 - A Clinical Phase 3 Study of VLA1553 in Adult Participants With Human Immunodeficiency Virus (HIV) Phase 3